Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Proactive Investors द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Proactive Investors या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Player FM - पॉडकास्ट ऐप
Player FM ऐप के साथ ऑफ़लाइन जाएं!
Player FM ऐप के साथ ऑफ़लाइन जाएं!
Voyageur Pharmaceuticals begins human testing for advanced Barium contrast products
Manage episode 460961371 series 2891889
Proactive Investors द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Proactive Investors या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce the commencement of human testing for the company's latest suite of barium contrast products, designed to optimize radiographic examinations of the gastrointestinal tract. The product lineup, including SmoothX, SmoothHD, SmoothLD, VisionHD, and VisionLD, is tailored to provide enhanced clarity, detail, and versatility for both adult and pediatric imaging applications. Willis emphasized the importance of this milestone, as it represents a critical step toward the company's goal of entering the Canadian market in 2025. The human testing process is being conducted in two phase with Phase 1 in Q1 2025 and will focus on assessing product performance based on key indicators such as imaging quality, diagnostic yield, contrast administration success rates, detection sensitivity, and patient safety. The company says some additional metrics will include patient satisfaction, procedure completion rates, adverse event rates, and compliance rates will also be closely monitored. These advanced formulations are designed to meet diverse clinical needs, ensuring high performance while maintaining safety and ease of use for patients. Voyageur aims to set a new standard in barium contrast agents, offering both precision and reliability in diagnostic imaging. This testing phase is an essential step in achieving regulatory approval and market readiness. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough,
…
continue reading
614 एपिसोडस
Manage episode 460961371 series 2891889
Proactive Investors द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Proactive Investors या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce the commencement of human testing for the company's latest suite of barium contrast products, designed to optimize radiographic examinations of the gastrointestinal tract. The product lineup, including SmoothX, SmoothHD, SmoothLD, VisionHD, and VisionLD, is tailored to provide enhanced clarity, detail, and versatility for both adult and pediatric imaging applications. Willis emphasized the importance of this milestone, as it represents a critical step toward the company's goal of entering the Canadian market in 2025. The human testing process is being conducted in two phase with Phase 1 in Q1 2025 and will focus on assessing product performance based on key indicators such as imaging quality, diagnostic yield, contrast administration success rates, detection sensitivity, and patient safety. The company says some additional metrics will include patient satisfaction, procedure completion rates, adverse event rates, and compliance rates will also be closely monitored. These advanced formulations are designed to meet diverse clinical needs, ensuring high performance while maintaining safety and ease of use for patients. Voyageur aims to set a new standard in barium contrast agents, offering both precision and reliability in diagnostic imaging. This testing phase is an essential step in achieving regulatory approval and market readiness. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough,
…
continue reading
614 एपिसोडस
सभी एपिसोड
×प्लेयर एफएम में आपका स्वागत है!
प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।